Do you consider MET amplification in your first-line treatment decisions for patients with metastatic NSCLC?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Colorado Cancer Center
Answered on
Not at present and nothing is FDA approved or NCCN guidelines. Second line or later yes, especially on a trial
Join for free or sign in to see the full answer